|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:antineoplastic_agent
|
|
gptkbp:ATCCode
|
L01BC02
|
|
gptkbp:brand
|
gptkb:Carac
gptkb:Efudex
Adrucil
Fluoroplex
|
|
gptkbp:CASNumber
|
51-21-8
|
|
gptkbp:category
|
gptkb:World_Health_Organization_essential_medicine
gptkb:pyrimidine_analog
DNA synthesis inhibitor
|
|
gptkbp:chemicalFormula
|
C4H3FN2O2
|
|
gptkbp:combines
|
gptkb:leucovorin
gptkb:irinotecan
gptkb:oxaliplatin
gptkb:cisplatin
|
|
gptkbp:discoveredBy
|
1957
Charles Heidelberger
|
|
gptkbp:eliminationHalfLife
|
10-20 minutes
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:IUPACName
|
5-fluoropyrimidine-2,4(1H,3H)-dione
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits thymidylate synthase
|
|
gptkbp:metabolism
|
gptkb:dihydropyrimidine_dehydrogenase
|
|
gptkbp:molecularWeight
|
130.08 g/mol
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:routeOfAdministration
|
topical
intravenous
|
|
gptkbp:sideEffect
|
gptkb:hand-foot_syndrome
nausea
vomiting
diarrhea
mucositis
myelosuppression
|
|
gptkbp:synonym
|
5-FU
|
|
gptkbp:usedFor
|
gptkb:cancer
gptkb:bladder_cancer
gptkb:actinic_keratosis
colorectal cancer
esophageal cancer
pancreatic cancer
head and neck cancer
gastric cancer
anal cancer
basal cell carcinoma
|
|
gptkbp:bfsParent
|
gptkb:Efudex
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
fluorouracil
|